N-(3-Chloro-4-fluorobenzyl)-1,4-dihydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide

ID: ALA3125970

Chembl Id: CHEMBL3125970

PubChem CID: 76321849

Max Phase: Preclinical

Molecular Formula: C16H11ClFN3O4

Molecular Weight: 363.73

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NCc1ccc(F)c(Cl)c1)c1c(O)c2cccnc2n(O)c1=O

Standard InChI:  InChI=1S/C16H11ClFN3O4/c17-10-6-8(3-4-11(10)18)7-20-15(23)12-13(22)9-2-1-5-19-14(9)21(25)16(12)24/h1-6,22,25H,7H2,(H,20,23)

Standard InChI Key:  ZMWNOXHZOQBNOQ-UHFFFAOYSA-N

Associated Targets(Human)

HOS (906 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
pol Human immunodeficiency virus type 1 integrase (9041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 363.73Molecular Weight (Monoisotopic): 363.0422AlogP: 2.06#Rotatable Bonds: 3
Polar Surface Area: 104.45Molecular Species: ACIDHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 4.12CX Basic pKa: 0.43CX LogP: 1.33CX LogD: -1.48
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.62Np Likeness Score: -1.43

References

1. Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR..  (2014)  Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.,  57  (4): [PMID:24471816] [10.1021/jm401902n]
2. Wang Y, Gu SX, He Q, Fan R..  (2021)  Advances in the development of HIV integrase strand transfer inhibitors.,  225  [PMID:34425310] [10.1016/j.ejmech.2021.113787]

Source